Department of Psychiatry, University of California, San Francisco, California, USA.
Critical Care Medicine, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.
Thorax. 2018 May;73(5):439-445. doi: 10.1136/thoraxjnl-2017-211090. Epub 2018 Feb 24.
Two distinct acute respiratory distress syndrome (ARDS) subphenotypes have been identified using data obtained at time of enrolment in clinical trials; it remains unknown if these subphenotypes are durable over time.
To determine the stability of ARDS subphenotypes over time.
Secondary analysis of data from two randomised controlled trials in ARDS, the ARMA trial of lung protective ventilation (n=473; patients randomised to low tidal volumes only) and the ALVEOLI trial of low versus high positive end-expiratory pressure (n=549). Latent class analysis (LCA) and latent transition analysis (LTA) were applied to data from day 0 and day 3, independent of clinical outcomes.
In ALVEOLI, LCA indicated strong evidence of two ARDS latent classes at days 0 and 3; in ARMA, evidence of two classes was stronger at day 0 than at day 3. The clinical and biological features of these two classes were similar to those in our prior work and were largely stable over time, though class 2 demonstrated evidence of progressive organ failures by day 3, compared with class 1. In both LCA and LTA models, the majority of patients (>94%) stayed in the same class from day 0 to day 3. Clinical outcomes were statistically significantly worse in class 2 than class 1 and were more strongly associated with day 3 class assignment.
ARDS subphenotypes are largely stable over the first 3 days of enrolment in two ARDS Network trials, suggesting that subphenotype identification may be feasible in the context of clinical trials.
在临床试验入组时使用数据已经确定了两种不同的急性呼吸窘迫综合征(ARDS)亚表型;这些亚表型是否随时间持久仍不清楚。
确定 ARDS 亚表型随时间的稳定性。
对 ARDS 两项随机对照试验(ARDS 网络的 ARMA 试验肺保护性通气[473 例患者;随机分配到低潮气量]和 ALVEOLI 试验低与高呼气末正压[549 例患者])的数据进行二次分析。应用潜在类别分析(LCA)和潜在转变分析(LTA)分析第 0 天和第 3 天的数据,与临床结局无关。
在 ALVEOLI 试验中,LCA 表明第 0 天和第 3 天 ARDS 有两个潜在类别存在强烈证据;在 ARMA 试验中,第 0 天比第 3 天的两个类别证据更强。这两个类别的临床和生物学特征与我们之前的工作相似,并且在很大程度上是稳定的,尽管第 2 类在第 3 天表现出进行性器官衰竭的证据,与第 1 类相比。在 LCA 和 LTA 模型中,大多数患者(>94%)从第 0 天到第 3 天保持在同一类别。第 2 类的临床结局明显比第 1 类差,与第 3 天的类别分配相关性更强。
在两项 ARDS 网络试验的入组最初 3 天内,ARDS 亚表型在很大程度上是稳定的,这表明在临床试验背景下进行亚表型识别是可行的。